Time to recurrence of metastatic melanoma not associated with survival rates

Source: Healio, May 2019

In patients with metastatic melanoma, the timing of advanced disease was not associated with the timing of first distant recurrence, according to a multicentric cohort study.

Study subjects were enrolled in the French MelBase database from March 1, 2013, to Sept. 1, 2017, and were treated with first-line immunotherapies, targeted therapies or chemotherapy or were in open clinical trials with at least 3 months of follow-up.

Data for 638 adults with unresectable stage III or IV melanoma were analyzed, including timing of primary excision, first distant recurrence, treatment commencement, disease progression and death; 274 patients were treated with first-line immunotherapies, 180 were treated with targeted therapies, 132 were in open clinical trials and 52 received chemotherapy.